Irene Roldan
Payments from drug & device makers
Across 107 payments — averaging $26.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$1K
- Johnson & Johnson$767
- Sumitomo Pharma America, Inc.$202
- Medtronic$127
- Urovant Sciences Inc$122
- Pfizer$85
- plus $459 from 12 others
What the payments were for
- Food & beverage$2,12675%
- Education$72425%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 27 | $1,087 |
| Johnson & Johnson(2 entities) | 27 | $767 |
| Sumitomo Pharma America, Inc. | 11 | $202 |
| Medtronic | 7 | $127 |
| Urovant Sciences Inc | 7 | $122 |
| Pfizer | 5 | $85 |
| Dendreon Pharmaceuticals LLC | 4 | $82 |
| Verity Pharmaceuticals Inc. | 4 | $74 |
| AbbVie | 3 | $63 |
| Sun Pharmaceutical Industries Inc. | 2 | $46 |
| 180 Medical, Inc. | 2 | $38 |
| Novartis | 2 | $29 |
| Axonics, Inc. | 1 | $24 |
| Merck | 1 | $23 |
| Tolmar, Inc. | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Bayer | 1 | $19 |
| Olympus America Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRUFILL$120
How this compares
$2,850 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 125 | $96,408 |
| GemtesaVibegron | 129 | $81,697 |
| TrelstarTriptorelin Pamoate | 19 | $22,500 |
| PremarinEstrogens, Conjugated | 41 | $18,011 |
| Tamsulosin Hcl | 884 | $9,911 |
| Tadalafil | 54 | $6,359 |
| Methenamine Hippurate | 48 | $3,907 |
| Dutasteride | 72 | $1,943 |
| Bicalutamide | 46 | $1,883 |
| Testosterone Cypionate | 51 | $1,512 |
| Solifenacin Succinate | 19 | $1,438 |
| Oxybutynin Chloride ErOxybutynin Chloride | 56 | $1,409 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 80 | $1,259 |
| Finasteride | 98 | $1,221 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 57 | $1,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,087 | $96,408125 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $202 | $81,697129 claims |
| Verity Pharmaceuticals Inc.Trelstar | $74 | $22,50019 claims |
| PfizerPremarin | $85 | $18,01141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Miami
- Stephanie MompointMiami$4.5M
- Itsel Cardenas RamonMiami$1M
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- John HuffakerVenice$8M
- Miguel TrujilloMiami Gardens$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.